What were Dishman Carbogen Amcis Ltd's latest quarterly results?
Dishman Carbogen Amcis Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -360.0%
- Revenue Growth YoY: +5.6%
- Operating Margin: 16.0%
Dishman Carbogen Amcis Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 17.0. ROE: -0.3%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Dishman Carbogen Amcis Ltd's latest quarterly results (Dec 2025) show
Dishman Carbogen Amcis Ltd's current PE ratio is 17.0x.
Dishman Carbogen Amcis Ltd's price-to-book ratio is 0.3x.
Dishman Carbogen Amcis Ltd's fundamental strength based on key financial ratios
Dishman Carbogen Amcis Ltd has a debt-to-equity ratio of N/A.
Dishman Carbogen Amcis Ltd's return ratios over recent years
Dishman Carbogen Amcis Ltd's operating cash flow is positive (FY2025).
Dishman Carbogen Amcis Ltd currently does not pay a significant dividend (yield 0.00%).
Dishman Carbogen Amcis Ltd's shareholding pattern (Dec 2025)
Dishman Carbogen Amcis Ltd's promoter holding has remained stable recently.
Dishman Carbogen Amcis Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Dishman Carbogen Amcis Ltd may be worth studying
Dishman Carbogen Amcis Ltd investment thesis summary:
Dishman Carbogen Amcis Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.